[Pharmacokinetics of dioxonium].
An investigation in the pharmacokinetics of a new peripheral muscle relaxant dioxonium and of its carbon-labeled analogue (with respect to the N-methyl groups) was carried out. An intravenous administration of dioxonium-C14 was found to bring about a biphasic change in radioactivity of the blood plasma. The stoppage of curarization, irrespective of a dioxonium dose, is seen to occur at a definite radioactivity level in the blood plasma. Major radioactivity following introduction of dioxonium-C14 is observed in the organism of the rats in the skeletal muscles and in the kidneys. The drug is eliminated from the organism through the kidneys in an unchanged and pharmacologically active form.
D000818:Animals; D002250:Carbon Radioisotopes; D002415:Cats; D004148:Dioxolanes / Q000378:metabolism / Q000494:pharmacology*; D004149:Dioxoles / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007700:Kinetics; D008657:Metabolic Clearance Rate / Q000187:drug effects; D009125:Muscle Relaxants, Central / Q000378:metabolism / Q000494:pharmacology*; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors
D002250:Carbon Radioisotopes; D004148:Dioxolanes; D004149:Dioxoles; D009125:Muscle Relaxants, Central; D010880:Piperidines; C012938:dioxonium
Farmakokinetika dioksoniia